Prescription drug · BLA
Aimovig (Erenumab-aooe) NDC 55513-843
Erenumab 140 mg/mL · Injection, Solution · Subcutaneous · Amgen, Inc
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 55513-843-00 | 55513084300 | 1 SYRINGE in 1 CARTON (55513-843-00) / 1 mL in 1 SYRINGEMarketed from Mar 15, 2019 | |
| 55513-843-01 | 55513084301 | 1 SYRINGE in 1 CARTON (55513-843-01) / 1 mL in 1 SYRINGEMarketed from Mar 15, 2019 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Aimovig
- Generic name (nonproprietary)
- erenumab-aooe
- Active ingredients
- Erenumab — 140 mg/mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Labeler
- Amgen, IncNDC labeler code 55513
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761077
- Marketing start
- Listing expires
- Identifiers
- Product ID 55513-843_78a567c7-6a18-416e-b9c4-b9360b0ef97aSPL ID 78a567c7-6a18-416e-b9c4-b9360b0ef97aSPL set ID b998ed05-94b0-47fd-b28f-cddd1e128fd8RxCUI 2045627, 2045632, 2045636, 2045638, 2056669, 2056670, 2056680, 2056681, 2120193, 2120195, 2120198, 2120199UNII I5I8VB78VTUPC 0000000000000
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N455513084300followed by a unit qualifier and the quantityPackage 55513-0843-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
AIMOVIG is indicated for the preventive treatment of migraine in adults. AIMOVIG is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 55513-843
- What is NDC 55513-843?
- 55513-843 is the product NDC for Aimovig (erenumab-aooe), Erenumab 140 mg/mL injection, solution, listed with the FDA by Amgen, Inc. It has 2 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Aimovig (Erenumab-aooe).
- What is the active ingredient?
- Erenumab.
- Who is the labeler?
- Amgen, Inc, NDC labeler code 55513. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Aimovig?
- 3 other product NDCs are listed under this name. See all Aimovig NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Aimovig products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Aimovigerenumab-aooe | Erenumab 140 mg/mL | Injection, SolutionSubcutaneous | Amgen, Inc | 55513-842 | 55513-0842-01 |
| Aimovigerenumab-aooe | Erenumab 70 mg/mL | InjectionSubcutaneous | Amgen, Inc | 55513-840 | 55513-0840-01 |
| Aimovigerenumab-aooe | Erenumab 70 mg/mL | InjectionSubcutaneous | Amgen, Inc | 55513-841 | 55513-0841-0055513-0841-01 |
Other NDCs under BLA 761077
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Aimovigerenumab-aooe | Erenumab 140 mg/mL | Injection, SolutionSubcutaneous | Amgen, Inc | 55513-842 |
| Aimovigerenumab-aooe | Erenumab 70 mg/mL | InjectionSubcutaneous | Amgen, Inc | 55513-840 |
| Aimovigerenumab-aooe | Erenumab 70 mg/mL | InjectionSubcutaneous | Amgen, Inc | 55513-841 |